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Pathogenesisa member of the AID/APOBEC family of deaminases, is a restriction factor for
human immunodeﬁciency virus (HIV). In the absence of the viral Vif protein hA3G is packaged into virions
and during reverse transcription in a recipient cell it deaminates cytosines, leading to G→A hypermutation
and inactivation of the viral DNA. Unlike humans, who carry seven APOBEC3 genes, mice only carry one,
mA3. Thus the role of mA3 in restriction of retroviral infection could be studied in mA3 −/− knockout mice,
where the gene is inactivated. M-MuLV-infected mA3 −/− mice showed substantially higher levels of
infection at very early times compared to wild-type mice (ca. 2 logs at 0–10 days), particularly in the bone
marrow and spleen. Restriction of M-MuLV infection was studied ex vivo in primary bone marrow-derived
dendritic cells (BMDCs) that express or lack mA3, using an M-MuLV-based retroviral vector expressing
enhanced jellyﬁsh green ﬂuorescent protein (EGFP). The results indicated that mA3 within the virions as well
as mA3 in the recipient cell contribute to resistance to infection in BMDCs. Finally, M-MuLV-infected mA3 +/+
mice developed leukemia more slowly compared to animals lacking one or both copies of mA3 although the
resulting disease was similar (T-lymphoma). These studies indicate that mA3 restricts replication and
pathogenesis of M-MuLV in vivo.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe AID/APOBEC family of cytidine deaminases plays diverse roles
in cellular physiology. Evolutionarily the original gene is thought to be
APOBEC2, from which AID, APOBEC1 and APOBEC3 evolved (Con-
ticello et al., 2005). These proteins have one or two cytidine
deaminase domains (CDDs), one of which is catalytically active.
APOBEC1 edits single C residues to U on the mRNA encoding
apolipoprotein B (ApoB) resulting in translation of a truncated form
of ApoB with a different biological function (Teng et al., 1993). AID is
involved in class switch recombination in B cells by randomly editing
dC residues to dU in the immunoglobulin gene locus, causing
hypermutation (Muramatsu et al., 2000); the function of APOBEC2 is
unknown. APOBEC3 genes are of great interest because they mediate
resistance to viral infections, and retroviruses in particular.l rights reserved.Studies on the vif gene of HIV identiﬁed human APOBEC3G, 3F and
3H(hA3G, hA3H and hA3F) as host factors that affect viral spread
(Mariani et al., 2003; Sheehy et al., 2002; Zhang et al., 2003) (OhAinle
et al., 2006). Restriction of HIV infection by hA3G and the counter-
action of this restriction by Vif have been extensively studied and
reviewed (Cullen, 2006; Holmes et al., 2007). In the absence of Vif (i.e.
infection with vif-negative HIV mutants), hA3G is packaged into
newly forming viral particles. Upon infection of a recipient cell, hA3G
deaminates cytosines in the minus strand DNA during reverse
transcription, resulting in G to A mutations in the reverse-transcribed
plus strand DNA (Harris et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003). This change leads to non-functional viral DNA. Vif counteracts
hA3G by binding and targeting it for ubiquitination (Mariani et al.,
2003); as a result little or no hA3G is packaged into newly forming
virions, and reverse transcription can proceed normally. The impor-
tance of hA3 is reﬂected by extensive genomic duplications resulting
in 7 different hA3 genes (hA3A–H), of which hA3B, hA3DE, hA3F and
hA3G have activity against HIV (Bishop et al., 2004; Dang et al., 2006;
Doehle et al., 2005a; Liddament et al., 2004; Rose et al., 2005;
Fig. 1.M-MuLV infection in C57/Bl6 and mA3−/−mice. Neonatal mice were inoculated i.
p. with M-MuLV. At 6, 8, 10 and 12 days post inoculation, the animals were sacriﬁced
and single cell suspensions were prepared from bone marrow, thymus and spleen. The
levels of infection (infectious centers (ICs)/106 cells plated) are shown. Each point
represents results from one animal. Circles, C57/Bl6; diamonds, mA3−/−. Mean values
are indicated by horizontal bars. (A) Bone marrow, (B) spleen, (C) thymus.
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members affect the mobility of ubiquitous human retrotransposons
(LTR-retrotransposons such as HERVs and non-LTR elements such as
LINEs and SINEs) that make up a substantial fraction of the human
genome(Bogerd et al., 2006; Lee et al., 2008; Muckenfuss et al., 2006;
Stenglein and Harris, 2006). Several hA3s also restrict hepatitis B virus
by cytidine deamination (Suspene et al., 2005; Turelli et al., 2004).
Unlike humans, mice have only one copy of the APOBEC3 gene
(mA3). Since there is only one mA3 gene in mice, any retrovirus that is
subject to APOBEC3 restriction would be affected by this one gene.
This ﬁnding makes possible a genetic study of mA3 since a single
genetic inactivation would eliminate its activity from mice. In this
report we used mA3 −/−mice to test the hypothesis that mA3 restricts
Moloney murine leukemia virus (M-MuLV) replication. M-MuLV is a
simple gamma retrovirus and does not encode any known vif analog.
mA3 can be incorporated into HIV virions and is not degraded by Vif;
moreover mA3 restricts HIV by cytidine deamination. Conversely
hA3G can be incorporated into MLV-based vectors and restrict
infection in vitro (Abudu et al., 2006; Doehle et al., 2005b; Kobayashi
et al., 2004). However, previous studies on the effects of mA3 onMuLV
infection have been less clear. Some studies indicated that MuLV is
resistant to mA3 because it is not efﬁciently packaged into virions
(Doehle et al., 2005b; Kobayashi et al., 2004; Zhang et al., 2008), or
because the MuLV protease degrades the full-length form of the
protein in the virion (Abudu et al., 2006). However, other studies
reported efﬁcient packaging of mA3 intoMuLV virions and subsequent
inhibition of infection (Browne and Littman, 2008; Mariani et al.,
2003; Rulli et al., 2008). The emerging consensus is that mA3 can
indeed be packaged into MuLV virions, and that mA3 does restrict
MuLV infection in vitro, although the degree of restriction is less than
for hA3G (or mA3) on HIV (Browne and Littman, 2008; Rulli et al.,
2008; Zhang et al., 2008). However, mA3 does not induce cytidine
deamination when incorporated into M-MuLV virions (Browne and
Littman, 2008; Rulli et al., 2008).
In this study we utilized the mA3 insertional knockout animals to
test if mA3 restricts M-MuLV infection in vivo, by measuring rates of
initial infection, disease progression and pathogenesis in these animals
compared to their wild-type counterparts. We also employed primary
bone marrow-derived dendritic cells (BMDCs) from these mice to
examine ifmA3 inhibitsM-MuLV infection in vitro.We found thatmA3
plays a role in reducing viral replication and pathogenicity of M-MuLV.
Results
Effects of mA3 on in vivo infection by M-MuLV
Previous studies have indicated that MuLVs are relatively resistant
to mA3 in vitro (Abudu et al., 2006; Doehle et al., 2005b; Kobayashi et
al., 2004), although other recent studies have reported that mA3 does
in fact restrict MuLV infection (Browne and Littman, 2008; Rulli et al.,
2008). Since these studies were carried out using tissue culture cells
transfected with mA3 expression vectors, we wished to determine if
endogenous levels of mA3 had any effect on MuLV infection in vivo in
mice. To this endwe compared in vivo infection byMoloneyMuLV (M-
MuLV) in mA3 homozygous knock-out (−/−) mice vs. wild-type (+/+)
animals. The mA3 −/− mice used in these studies (initially from 129/
Ola embryos) were at the ninth back-cross generation to C57Bl6 (B6)
mice. Neonatal mA3 and B6 mice were inoculated intraperitoneally
with an M-MuLV stock, and levels of infection in bone marrow, spleen
and thymus were measured at different times post-infection (6–
12 days) by an infectious center assay as described previously (Lander
et al., 1999). As shown in Fig. 1, mA3 −/− animals showed more rapid
early infection in all tissues than their wild-type counterparts up to
10–12 days post-infection. Differences in infection levels were
substantial at the earlier time points (8–10 days, typically 2–3 logs),
and they differed signiﬁcantly by a two-tailed T-test at 8 (pb0.04), 10(pb0.03) and 12 days (pb0.01 for spleen and pb0.0003 for thymus
and bone marrow). These results suggested that mA3 does restrict M-
MuLV infection in vivo, with the effects being evident by slower
establishment of initial infection in mA3 −/− vs. +/+ B6 mice.
Since the mA3 −/− mice used in Fig. 1 might not have been
completely isogenic with B6, it was possible that some or all of the
effects observed could have reﬂected other genes besides mA3. To
exclude this possibility, the mA3 −/− mice were crossed with B6 mice
and the heterozygous mA3 +/− F1 animals were intercrossed to
generate F2 animals. These litters were inoculated with M-MuLV and
the levels of infection in bone marrow, spleen and thymus at 6–
14 days were measured as in Fig. 1. Each animal was genotyped for
mA3 status, and the resultswere plotted according to genotype (+/+, +/−
or −/−) as shown in Fig. 2. These results again indicated that mA3 +/+
animals established infectionmore slowly than animalsmA3 −/−mice,
although in this case differences between the different genotypes
were smaller, especially after day 10 post-infection. The bone marrow
was of particular interest, since we previously showed that the
efﬁciency of M-MuLV leukemogenesis is dependent on establishing
infection in the bone marrow at early times (Belli and Fan, 1994). As
shown in Fig. 2A, 5/7mA3 +/+mice showed nomeasurable infection at
6 or 8 days post infection, while 6/6 −/− animals showed infection
ranging from 1×100 to 2×103/106 cells. More extensive infection was
Fig. 2. M-MuLV infection in mA3+/− F2 mice. Neonatal mice from inter-crosses between two mA3 +/− mice were inoculated i.p. with M-MuLV. At 6, 8, 10, 12 and 14 days post-
inoculation, the animals were sacriﬁced and single cell suspensions were prepared from bone marrow, thymus and spleen. Genotypes of the animals were determined. The levels of
infection (ICs/106 cells plated) are shown. Each point represents results from one animal. Squares, mA3+/+ mice; triangles, mA3+/− mice; circles, mA3−/− mice. Mean values are
indicated by horizontal bars. (A) Bone marrow, (B) spleen, (C) thymus.
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8 days; the levels of infection in the thymus at these early times were
lower than in the bonemarrowand spleen, as we described previously
(Davis et al., 1987).
To ensure that the differences in infection were signiﬁcant, larger
numbers of animals were analyzed at day 10 as shown in Fig. 2. In all
tissues, mA3 −/− animals showed signiﬁcantly higher levels of
infection than mA3 +/+ mice (Table 1). In the bone marrow the diffe-
rences were greater than 2.5 logs. Therewas a trend towards statistical
signiﬁcance in the differences between +/− and +/+ animals in the bone
marrow and spleen, and the levels of infection in the bone marrow ofTable 1
M-MuLV Infection levels at 10d post-inoculation in mA3 F2 micea
Genotype Bone marrow Spleen Thymus
+/+ 7.8×101 3.7×102 6.2×102
+/− 6.9×103 pb0.093 3.4×103 pb0.11 8.4×102 pb0.70
−/− 3.7×104 pb0.0046 1.3×104 pb0.00001 8.0×103 pb0.053
a Mean values for infectious centers (per 106 cells) in different tissues for animals
shown in Fig. 2 at 10 days post-infection, according to genotype are shown. Statistical
analyses (2-tailed T-test) for +/− and −/− animals in comparison to +/+ animals are
shown; comparisons reaching statistical signiﬁcance are in bold.heterozygous +/− and homozygous −/− mice appeared similar. Past
10 days, the levels of infection in +/+ animals increased so that by 12
and 14 days levels of infection in all organs resembled those of their −/−
and +/− littermates. Taken together, these results indicated that mA3
has a signiﬁcant effect in controlling early infection in M-MuLV-
inoculatedmice, particularly in the bonemarrow.However, by 2weeks
post-inoculation M-MuLV established similar levels of infection in
mA3+/+ and −/− animals, consistentwith its ability to induce leukemia.
Effects of mA3 on in vitro M-MuLV infection of BMDCs
We previously showed that early infection in the bone marrow is
important for efﬁcient leukemogenesis by M-MuLV (Belli and Fan,
1994). Moreover, the early difference in infection levels was greatest in
this tissue when comparing mA3 −/− and wild-type mice as shown
above. Thus we were interested if mA3 could restrict in vitro infection
of particular bone marrow cells. Dendritic cells (DCs) from humans
and mice have been shown to express human A3s and mA3
respectively (Okeoma et al., 2007; Pion et al., 2006). Therefore we
tested whether M-MuLV could infect BMDCs in vitro, and whether the
levels of infection were different in BMDCs derived frommA3 +/+ and
−/− mice.
Fig. 4. Pathogenesis by M-MuLV in mA3 −/− animals. Kaplan–Meier plots of survival of
animals from mA3 +/− intercrosses after i.p. inoculation with M-MuLV. Dashed line,
mA3−/− animals (n=13; median latency 208 days); dotted line, mA3+/− animals (n=17;
median latency 178 days); and the solid line, mA3+/+ animals (n=10, median latency
269.5 days).
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enhanced green ﬂuorescent protein (LEGFP-N1) was used. Vector
stocks were generated by co-transfecting the 293T-based ecotropic
MuLV packing cell line Phoenix-eco with the vector plasmid pLEGFP-
N1 along with expression plasmids for HA epitope-tagged mA3 or
the backbone plasmid pcDNA3.1. There are actually two isoforms of
mA3 that result from the presence or absence of exon 5 in the
spliced mA3 mRNA (Abudu et al., 2006); these two isoforms also
encode a number polymorphic amino acids (Takeda et al., 2008).
cDNAs for epitope-tagged forms of both proteins (mA3HA and
mA3Δexon5HA) were used to generate vector stocks containing
either mA3 isoform. Tissue culture supernatants were harvested,
concentrated and then tested for the presence of vector and mA3 by
SDS-PAGE and western blot analyses with antibodies for MuLV CA or
HA epitopes respectively as shown in Fig. 3A. The amounts of vector
particles present in the three stocks were similar, as measured by
the presence of CA protein (anti-p30). Moreover, mA3 could be
readily detected by the anti-HA antibody, and the same relative
amounts of mA3 were present regardless of whether exon5 was
present, consistent with previous reports (Browne and Littman,
2008; Mariani et al., 2003; Rulli et al., 2008).
The vector pseudovirions with or without mA3 were then tested
for in vitro infectivity in primary bone marrow-derived dendritic cells
(BMDCs) derived from +/+ or −/− mice. The extents of infection were
measured by ﬂow cytometry for the EGFP reporter protein on the
vector. Since C57Bl6 mice only express the Δexon5 form of mA3
(Santiago et al., 2008; Takeda et al., 2008), the results shown in Fig. 3B
are for this form of mA3, although similar results also were obtained
for wild-type mA3 (not shown). The results indicated that MuLV
restriction resulted both from the presence of mA3 in the virus
particles, as well as from the presence of mA3 in the infected cells. The
effects of mA3 in the virus particles were evident by comparison of the
MuLV vector lacking or containingmA3 in either the +/+ or −/− BMDCs.
The presence of Δexon5 mA3 in particles reduced infectivity by 45–
50% compared to particles lackingmA3 in bothmA3 +/+ and −/− BMDCFig. 3. M-MuLV infection of BMDCs. (A) Protein levels in LEGFP-N1 vector stocks
produced in the absence (pcDNA 3.1) or presence ofmA3HA ormA3Δexon5HA.Western
blots for mA3 (anti-HA) and MuLV CA protein (anti-p30) are shown. All samples were
run on the same gel. (B) After standardization of viral stocks by RT-PCR for vector RNA,
BMDCs from mA3 +/+ and −/− mice were infected by vector produced in the absence
(light gray) or presence (dark gray) of mA3Δexon5HA. FACS analysis for EGFP
expression after 24 h determined infection levels as shown.preparations. The effect of mA3 in the recipient cells was apparent by
comparing the efﬁciencies of infection for the same vector preparation
in +/+ vs. −/− BMDCs. For both vector preparations there was a ca. 40%
reduction in infectivity in +/+ BMDCs compared to −/− cells. In total the
effects of mA3 in virions combined with mA3 in the recipient cells
resulted in a ca. 3-fold reduction in infectivity (vector lacking mA3 in
−/− BMDCs compared to vector containing mA3 in +/+ cells).
Effects of mA3 status on pathogenesis by M-MuLV
In light of the effects of mA3 status on the rate of early M-MuLV
infection in the bone marrow and its ability to restrict infection of
BMDCs, we next investigated if there was an effect on M-MuLV-
induced pathogenesis. M-MuLV induces lymphoma (largely T-lym-
phoma) in B6 mice, and it seemed possible that knockout or reduction
in mA3 copies might accelerate the rate of disease development or
cause additional kinds of tumors. Neonatal F2 litters from F1 mA3 +/−
intercrosses were inoculated IP with M-MuLV and the animals were
observed for development of disease. Moribund animals were
sacriﬁced, subjected to gross pathological analysis, and enlarged or
abnormal tissues (thymus, spleen, lymph nodes and in some cases
kidneys) were obtained for DNA extraction or parafﬁn embedding. The
animals were also genotyped, and the results were tabulated
according to genotype. All but one of the +/+ animals, and all but
one of the +/− animals had tumors at the time of sacriﬁce; all −/−
animals had tumors. The time courses for mortality (Kaplan–Meier
plots) of the three genotypes are shown in Fig. 4. The time courses for
the −/− and +/− animals were similar, so the results for these two
groups were pooled. The median survival time for M-MuLV-infected
mA3 +/+ animals was 269.5 days, compared to 207.5 days for infected
animals missing at least one copy of the mA3 gene (−/− or +/−). The
survival of the infected mA3 +/+ animals was signiﬁcantly different
from that of the inoculated −/− or +/− animals (log rank test pb0.023
or by the Wilcoxon test pb0.021). Secondary analyses showed a
statistical difference in time to disease between +/+ and +/− animals
(log rank test pb0.021; Wilcoxon test pb0.011), but not between +/+
and −/− animals (log rank pb0.078;Wilcoxon pb0.092), due at least in
part to the lower number of −/− animals. Taken together, these results
indicated that mA3 reduces the kinetics of tumor induction by M-
MuLV, and that loss of one or both copies of the gene signiﬁcantly
increases the rate of disease development.
The gross pathology of the sacriﬁced animals indicated enlarged
thymus, spleen or lymph nodes for animals of all genotypes,
characteristic of the lymphoblastic lymphoma induced by M-MuLV
Table 2
Tumor types in M-MuLC-infected mice by mA3 genotype
Genotype T cella B/preB cellb Non T/B cellc
+/+ 4/8 3/8 1/8
+/− 12/14 1/14 1/14
−/− 9/12 2/12 1/12
a Tumors with TCRβ rearrangement with or without IgH rearrangement were
classiﬁed as T-cell lymphomas.
b Tumor tissues with IgK and IgH rearrangement were classiﬁed as B-lymphomas;
tumors with IgH but not IgK or TCRβ were classiﬁed as preB lymphomas.
c Tumor tissues that did not show any rearrangement in TCRβ, IgH, or IgK.
Fig. 5. Kidney tumors in mA3 −/− andmA3+/− animals. (A) H&E staining of kidney tissue
from an mA3−/− animal showing lymphocyte inﬁltrates. (B) Immunohistochemistry for
CD3 staining in the same kidney veriﬁed that inﬁltration was T-lymphoid. (C) H & E
staining of a tumor from an mA3+/− animal also shows lymphocyte inﬁltrates in the
kidney.
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diagnosis of the tumors was performed by testing tumor DNAs for
rearrangements of T-cell receptor beta (TCRβ), immunoglobulin Mu
heavy chain (IgH) and immunoglobulin kappa light chain (IgK) genes.
Tumors with TCRβ gene rearrangements (with or without IgH
rearrangements) were classiﬁed as T-lymphoid, those with IgK and
IgH rearrangements were classiﬁed as B-lymphoid, and thosewith IgH
but no IgK or TCRb rearrangementswere classiﬁed as preB (Hanecak et
al., 1988). As shown in Table 2, the great majority of tumors in all three
genotypes showed rearrangements in these genes, consistent with T-
lymphoma and to a lesser extent B- or preB-lymphomas. If anything
the −/− and +/− animals developed a higher percentage of pure T-
lymphomas. Thus, while loss of one or both mA3 alleles reduced the
time to tumor formation, it did not appear to expand the range of
tumor types observed.
Interestingly three out of 13 mA3 −/− animals and 2 out of 17 mA3
+/− animals showed evidence of tumor involvement in the kidneys, as
evidenced by visiblemasses on necropsy. In contrast none of the 10 +/+
animals showed this disease pattern. Histopathological analyses of the
kidneys from two of these animals are shown in Fig. 5. The tumor cells
were found to be lymphoid by H&E staining (Figs. 5A and C),
consistent with metasases from primary lymphoid organs. The tumor
inﬁltrates (localized or extensive) contained small round or oval cells
with non-cleaved nuclei that resembled tumor cells in the spleen or
thymus from the same animal (not shown). They were positive for
immunohistochemical staining for CD3, a marker for T-lymphoid cells
and tumors (Fig. 5B), indicating that they were of T-cell origin.
Discussion
In these experiments, we investigated if mA3 has an effect on M-
MuLV infection. Our approach was to employmA3 knockoutmice, and
to compare their rates of infection and pathogenesis to animals
containing the mA3 gene. Assays of M-MuLV in vivo infection and
pathogenesis provided both sensitive and relevant measures of mA3
restriction. The results indicated that mA3 signiﬁcantly delays esta-
blishment of M-MuLV infection at early times, particularly in the bone
marrow. At 6–10 days post-inoculation, the levels ofM-MuLV infection
in mA3 −/−mice were 2–3 logs higher than in mA3 +/+ animals in that
tissue. Clearly mA3 restriction of M-MuLV is not absolute, and by
2 weeks, the levels of infection approached equivalency in −/− and +/+
animals. Nevertheless mA3 +/+ animals developed M-MuLV-induced
leukemiasmore slowly (ca. 2months later on average) than inoculated
−/− mice. This was consistent with the less efﬁcient establishment of
bone marrow infection in +/+ mice, since we previously found that
efﬁcient establishment of early bone marrow infection is correlated
with the efﬁciency of M-MuLV-induced disease (Belli and Fan, 1994).
Whenwe initiated these experiments, it was unclear if therewould
be a difference between M-MuLV infection in mA3 +/+ and −/− mice.
While mA3 efﬁciently inhibits HIV-1 infection (Bishop et al., 2004;
Mariani et al., 2003), early reports indicated that MuLVs are resistant
to this factor (Doehle et al., 2005b; Kobayashi et al., 2004). This was
attributed to the exclusion of mA3 from MuLV (but not HIV-1)particles (Doehle et al., 2005b; Kobayashi et al., 2004) or degradation
of packaged mA3 by viral protease (Abudu et al., 2006). In the latter
case, mA3Δexon5 was reported to be relatively resistant to viral PR
(Abudu et al., 2006). On the other hand, recent reports have concluded
that both mA3 and mA3Δexon5 are efﬁciently packaged in MuLV
virions (Browne and Littman, 2008; Rulli et al., 2008), which are in
agreement with other early reports. In fact, the results shown in Fig.
3A are consistent with the conclusion of those investigators favoring
the packaging of mA3 into MuLV virions. Regardless of whether mA3
(or the Δexon5 version) is packaged into virions or not, our results
indicated that mA3 does indeed restrict M-MuLV infection in vivo
evenwhen the protein is not over-expressed. Since these experiments
were carried out in the B6 genetic background, these conclusions
predominantly pertain to the Δexon5 form of mA3.
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disease induction. Infected +/+ animals developed diseasemore slowly
than infected −/− and/or +/− mice. This was consistent with the fact
that infected +/+ animals show lower levels of infection in the bone
marrow (Fig. 2A) (and spleen, Fig. 2B) between days 6 and 10; early
bone marrow infection is correlated with efﬁcient disease induction
(Belli and Fan, 1994). The early bone marrow infection (perhaps
involving BMDCs) could result in defects in bone marrow stroma,
leading to extramedullary hematopoiesis (Davis et al., 1987; Li and
Fan, 1990) and/or early generation of mink cell focus-inducing (MCF)
env recombinants (Brightman et al., 1990). These preleukemic events
have been associated with efﬁcient M-MuLV leukemogenesis. It was
also interesting that heterozygous +/− animals showed more rapid
disease development than +/+ animals, similar to the faster rate of
disease for −/− animals. This might suggest that both mA3 gene copies
are required for relative resistance to M-MuLV leukemogenesis.
Indeed, at day 10 the levels of M-MuLV infection in the bone marrow
of +/− mice more closely resembled those of −/− animals than +/+
animals (Fig. 2A). Pathogenicity in +/− animals was not reported in two
recent reports involving differentMuLVs (acute disease induced by the
Friend complex) (Santiago et al., 2008; Takeda et al., 2008).
The kinds of disease arising in mA3 −/− animals were of interest. It
seemed possible that mA3 might affect the kinds of tumors, if the
protein were differentially expressed in different cells. Thus mA3 −/−
mice might show novel kinds of tumors compared to +/+ animals.
However, the −/− animals also developed T-lymphoma, which
indicated that the lack of mA3 did not expand the resulting tumor
types. In fact, a higher percentage of the infected −/− and +/− animals
developed T-lymphoma than the +/+ mice; the latter also showed
development of B- or preB-lymphomas. One possible explanation
could be related to the overall time required for disease development.
If the target cells for T-lymphoma (likely T-lymphoid progenitors in
the thymus) decrease with age while the targets for B-lymphoma do
not, then conditions where disease is induced more rapidly could
show higher percentages of T-lymphoma. Indeed, an SV40 enhancer-
driven variant of M-MuLV that induced disease with extremely long
latency (17 months) induced exclusively B-lymphomas (Hanecak et
al., 1988). In mouse strains where M-MuLV leukemogenesis is efﬁcient
(e.g. ca. 100 days for NIH Swiss mice), the tumors are almost
exclusively T-lymphoid (Brightman et al., 1988).
It was interesting that some −/− and +/− animals showed M-MuLV-
induced tumors at a novel anatomical site, the kidney. This location
has not been observed previously for M-MuLV-induced tumors, and
inoculated +/+ animals did not show kidney involvement by gross
pathology. These tumors appeared to represent T-lymphoma metas-
tases as shown in Fig. 5. In the future it will be interesting to study the
basis for the apparently more metastatic T-lymphomas in mA3 −/−
mice.
The mechanism(s) by which mA3 restricts MuLVs remain to be
determined. Several groups have reported that mA3 does not cause
cytidine deamination and DNA hypermutation during MuLV infection
(Browne and Littman, 2008; Rulli et al., 2008; Takeda et al., 2008),
which suggests that other mechanismsmay be involved. Indeed, it has
been reported that the cytidine deaminase activity of hA3G is not
required for its restriction of HIV (Bishop et al., 2006). Chiu et al. (2005)
have reported that HIV is restricted for infection by a low molecular
mass complex of hA3G in recipient resting human T-cells. It is possible
that thismechanismmayalso be applicable tomA3 restriction ofMuLV
in BMDCs. We therefore also employed the mA3 −/−mice to study M-
MuLV infection of BMDCs from mA3 +/+ and −/− animals. We used an
M-MuLV-derived vector expressing EGFP, which allowed quantiﬁca-
tion of infection by ﬂow cytometry. Co-expression ofmA3 in the vector
packaging cells allowed investigation of the role of packaged mA3 in
BMDC cell infection, while comparison of infection in BMDCs from −/−
vs. +/+ animals allowed investigation of the role ofmA3 in the recipient
cell. As shown in Fig. 3, the restriction ofMuLV bymA3 is inﬂuenced byboth mA3 brought in by the infecting virion, as well as by mA3 in the
infected cell. The presence of mA3 in the virion reduced infectivity by
approximately 50%. Similarly, the presence of mA3 in the recipient
BMDC also reduced infection by ca. 40%.
We have previously studied restriction by mA3 of another murine
retrovirus, mouse mammary tumor virus (MMTV; Okeoma et al.,
submitted for publication).We found thatmA3also restricts infectionof
MMTV invivo, and that restrictionwasmediatedbybothmA3packaged
in the virions as well as mA3 in the dendritic cells (Okeoma et al.,
submitted for publication). Thus mA3 restricts infection by two
different murine retroviruses, and in both cases the restriction is
partial. It will be interesting to compare the mechanisms of restriction
for these two viruses. The results obtained so far indicate that mA3 in
the virion aswell as in the recipient dendritic cell both contribute to the
restriction. Dendritic cells are known to be the ﬁrst targets for MMTV
infection. Whether these are also the initial targets for M-MuLV and if
DC infection affects M-MuLV-disease are under investigation. In
addition ongoing experiments are studying how M-MuLV and MMTV,
neither ofwhich apparently encodes a Vif-like function, avoid complete
restriction by mA3.
While this manuscript was in preparation, Santiago et al. (2008)
reported that the mouse resistance gene Rfv3 (recovery from Friend
virus gene-3) is in fact associatedwithmA3 status. A similar conclusion
was also reached in a recent report by Takeda et al. (2008). Rfv3 was
originally deﬁned on the basis of the ability of certain mouse strains to
recover from infection and rapid erythroid proliferation induced by the
Friend virus complex (consisting of the acute transforming Friend
Spleen Focus-forming virus, an ecotropic FriendMuLV [F-MuLV] helper
virus, and Lactate dehydrogenase-elevating virus). These recent reports
showed that Rfv3 maps to the same chromosomal region as mA3 and
that mouse strains harboring resistance alleles of Rfv3 (e.g. B6) encode
functional mA3 (predominantly the Δexon5 form) while Rfv3 sensitive
strains (e.g. Balb/c) encode defective or less active forms of mA3.
Moreover, mA3 −/− mice showed behavior similar to Rfv3 sensitive
strains in terms of rapid erythroid disease induced by the Friend virus
complex. In agreement with the results reported here for M-MuLV,
Takeda et al. (2008) also reported that infection with F-MuLV alone
showed a 2 logs higher infection inmA3 −/−mice compared to +/+mice
at 6 days post-infection, although effects on F-MuLV-induced leukemia
were not reported. The results of Santiago et al. (2008) and Takeda et al.
(2008) also differed from these results in that their infections were into
adult mice that can establish effective immune responses. Taken
together these two recent reports and our results indicate that mA3
restricts murine leukemia virus replication in vivo. Moreover our
studies with M-MuLV indicate that mA3 has long-term effects in
modulating M-MuLV-induced leukemogenesis.
Experimental methods
Cells
43-D cells are NIH3T3 ﬁbroblasts stably infected with wild type M-
MuLV. They were maintained in Dulbecco-modiﬁed Eagle's Medium
(DMEM) supplemented with 10% calf serum and antibiotics. The
Phoenix-eco cell line is an ecotropic MuLV-based packaging cell line
created from Human 293T cells (http://www.stanford.edu/group/
nolan/retroviral_systems/phx.html) was obtained from Dr. Garry
Nolan and was grown in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin and 100 μg/mL streptomycin. Bone marrow-derived den-
dritic cells (BMDCs) from mA3−/− and mA3+/+ mice were generated
according to published procedures (Lutz et al., 1999). Brieﬂy, bone
marrow cells from 10 day old mice were cultured for 8 days in RPMI
medium containing 10% FBS, 100 U/mL penicillin, 100 μg/mL
streptomycin, 0.05 mM 2-mercaptoethanol, and 10 ng/mL recombi-
nant murine-GM-CSF (Peprotech, Inc. Rocky Hill, NJ). BMDCs were
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(Sigma, Inc., St. Louis, MO) for 24 h. Differentiation into immature or
mature DCs was documented by ﬂow cytometry for cell-surface
expression of CD40 and anti-CD86. All cells were cultured at 37 °C
with 5% CO2.
Virus and vector production
To prepare M-MuLV viral stocks, 5×105 43-D cells (productively
infected NIH-3T3 cells), were seeded on 10 cm plates in growth
medium, and 24 h later media was changed. 24 h after the medium
change, supernatants were collected and passed through a .45 micron
ﬁlter. Supernatants were then divided into aliquots, frozen and stored
at −80 °C.
For generation of vector stocks, Phoenix-eco cells were plated at
2×106 cells per 10 cm plate 24 h prior to transfection. They were then
transiently transfected using the CalPhos mammalian transfection kit
(BD Biosciences, Palo Alto, Calif.) with 28 µg of total DNA per plate:
10 µg of pLEGFP-N1 M-MuLV based vector plasmid expressing
enhanced green ﬂuorescent protein (EGFP) (Clonetech) and 18 µg of
mA3 expression plasmids (pmA3HA, pmA3D5HA or control
pcDNA3.1). pmA3HA and pmA3D5HA were provided by Alan Rein
(Rulli et al., 2008). Cells were washed with phosphate-buffered saline
(PBS) 12 h post-transfection and re-fed with fresh media. 24 h post-
transfection, media was replaced with Optimem (Invitrogen, Carlsbad,
Calif.) supplemented with 2% FBS (10 mL per dish). 48 h post-
transfection media was collected and ﬁltered through a 0.45 micron
ﬁlter. Supernatants were then pooled and concentrated 500-fold using
a Centricon Plus-70, Ultracel-PL Membrane, 100 kDa (Millipore, USA).
Brieﬂy, Centricon units were sterilized with 70% ethanol, and washed
with 70 mL of 1×PBS. 70 mL of supernatant was applied to the ﬁlter
unit followed by centrifugation in a Beckman Allegra 6 centrifuge at
3000 rpm and 4 °C for 15 min. The ﬂow-through was removed and
additional supernatant media was applied to the unit, followed by
centrifugation under the same conditions for 30 min. To recover the
concentrated vector, the unit was inverted followed by centrifugation
at 1200 rpm for 1 min. The concentrated vector was stored in aliquots
at −80 °C.
Infectivity titrations
M-MuLV titers were determined by a focal immunoﬂuorescence
assay (FIA) as described previously (Lander et al., 1999). NIH-3T3 cells
were plated at 7×104 cells per 6 cm plate 24 h prior to infection. They
were pretreated with 1 mL of 2 µg/mL Polybrene in TD (Tris-buffered
saline lacking calcium and magnesium) 1 h prior to infection. The
polybrenewas then aspirated and 1 mL of diluted virus stock (ten-fold
serial dilutions) was applied, followed by incubation at 37 °C for 1 h,
after which 3 mL media was added to each plate. 4 days post infection
plates were stained for 1 h at 4 °C with the 538 env monoclonal
antibody. The plates were washed with PBS supplemented with 2%
FBS. The plates were then stained for 30 min at 4 °C with a secondary
antibody (ﬂuorescein-conjugated goat IgG fraction to mouse immu-
noglobulins, MP Bio) which was diluted 1:200 in 2%FBS/PBS. Plates
werewashed 3 times and then colonies of green cells were counted on
a microscope under UV illumination. Viral titers were calculated from
the numbers of ﬂuorescent colonies corrected for the dilution factors
of the viral stocks in each plate.
Infection levels in primary bone marrow, spleen and thymus were
measured in an analogous infectious center assay, as described
previously (Lander et al., 1999). Single cell suspensions (106 cells
and serial ten-fold dilutions) from animals at different times post-
inoculation (6–14 days) were co-cultivated with NIH-3T3 cells after
pretreatment with 1 mL of 2 µg/mL Polybrene in TD for 1 h, and after
24 h the non-adherent cells were aspirated. After 4 days, the infected
NIH-3T3 cell cultures were processed as above, and regions of focalimmunoﬂuorescence were counted. The number of infected hemato-
poietic cells per 106 cells was then calculated from the number of foci
of infection, corrected for the dilution factors of the seeded
hematopoietic cells.
Titrations of vector stocks were also performed on NIH-3T3 cells.
The cells were plated 24 h prior to infection at 2×105 cells per 6 cm
plate. Cells were pretreated and infected as above for viral titrations.
2 days post-infection the plates were observed under UV illumination,
and green ﬂuorescent cells (individuals or small groups) were
counted. Infectivity titers were calculated from the numbers of
ﬂuorescent cells/colonies, corrected for the dilution factors.
Animals
mA3 knockout animals were created by gene trap/ES cell
technology (Baygenomics) as described previously (Okeoma et al.,
2007). Brieﬂy, the beta-galactosidase (β gal) gene was randomly
inserted by way of a retroviral vector into an ES cell line derived from
129/Ola mouse embryos. Expression of the inserted β gal gene was
used to identify ES cells with insertions, and also to locate and
determine the sites of insertion. The ES cell with mA3 knocked out,
were selected and showed disruption by β gal in exon 4, resulting in a
fusion product of mA3 and β gal. This ES cell was then used to create
the knockout animals; ES cells were cultured and then injected into
129/Ola blastocytes by the Transgenic Knockout Shared Resource at
UCDavis. The resulting mA3 knockout mice were backcrossed to C57/
Bl6 (B6) mice and used in the ninth backcross generation to B6 for
these experiments. We previously showed that cells from these
animals lack functional mA3 protein (Okeoma et al., 2007).
Genotyping
Tail samples were obtained from animals and DNA was extracted
using the DNeasy Kit (Qiagen). PCR was performed on the samples to
identify the wildtype mA3 and the mA3 gene with the insertional
knockout cassette. Both PCR reactions utilized the same forward
primer in exon (4 5′-AAT TTA AAA AGT GTT GGA AGA AGT TTG TGG
ACA-3′); PCR which detected wildtype mA3 used a reverse primer
speciﬁc for exon (5 5′-TGA AGA GCT GGA AGG GAC CGA GAT GTA GCA
AGG-3′) and the PCR detecting the insertional knockout version of
mA3 utilized a reverse primer speciﬁc for the β gal cassette used to
create the insertional knockout (5′-CCA CAA CGG GTT CTT CTG TT-3′).
In vivo pathogenesis
Neonatal mice were inoculated intraperitoneally (IP) with 0.2 mL
of M-MuLV stock (5×105 to 1×106 IU/mL), as described previously
(Davis et al., 1985). The animals that were allowed to go to disease
were observed until they showed signs of disease, at which point they
were sacriﬁced and subjected to necropsy (Bundy et al., 1995).
Hematocrits were measured; spleen, thymi, lymph nodes and other
enlarged or abnormal organs were prepared for genomic DNA
extraction by phenol/chloroform isolation. Portions of tumors and
enlarged or abnormal tissues were also frozen and ﬁxed in
formaldehyde and embedded in parafﬁn.
Tumor diagnosis
Tumor diagnosis was conducted as described previously (Bundy
et al., 1995). In light of the fact that M-MuLV induces lymphoblastic
lymphomas (predominantly T-lymphoma) inmostmice (Brightman et
al., 1988), animals with enlarged thymus, spleen and/or lymph nodes
and normal hematocrits were considered presumptively to have
lymphoblastic lymphoma. To identify the types of lymphoma, cellular
DNAs from enlarged organs were analyzed for rearrangements of the
T-cell receptor beta (TCRβ), immunoglobulin mu heavy chain (IgM)
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digestion and Southern blot hybridization as described previously
(Brightman et al., 1988). Tumor tissues showing gene rearrangements
for TCRβ were classiﬁed as containing T-lymphoma, while those
containing IgK gene rearrangements were classiﬁed as containing B
lymphoma. Tumors that showed IgM rearrangements (but no TCRβ
rearrangements) were classiﬁed as containing B lymphoma or pre-B-
lymphoma, depending on whether the IgK gene showed rearrange-
ment as well.
Histopathological analysis
4–6 µm sections were cut from the parafﬁn blocks and studied by
light microscopy after staining with normalized hematoxilin-eosin
(H&E) and Congo red for amyloid procedures. In addition, standard
immunohistochemistry for CD3 and CD79 lymphocyte antigens were
carried out.
In vitro infection of BMDCs
BMDCs were infected with LEGFP-N1 vector stocks (vector alone,
vector containing mA3, or vector containing mA3Δ5) for 24 h. Cells
treated with 3 mg/mL of the reverse transcription inhibitor azidothy-
midine (AZT; Sigma, Inc.) at 37 °C for 2 h served as controls. Infection
assays were done by the spinoculation method, as previously
described (Courreges et al., 2007). Brieﬂy, BMDCs were plated in a
96-well plate at a cell density of 1×106 per well and vector stocks were
added to cells. The approximate MOIs were 0.03 NIH-3T3 infectious
units per cell. The platewas centrifuged at 1200 ×g for 120min at room
temperature. After centrifugation, the supernatants were discarded
and fresh RPMI complete medium was added to the cells. The cells
were cultured for 24 h prior to harvesting. Fluorescence-activated cell-
sorting (FACS) analysis for EGFP expression was used to detect
infection and data are presented as relative infectivity normalized to
viral RNA levels. All infectivity assays were done in triplicate; each
assay was performed a minimum of 3 times with similar results. The
results were normalized for the relative amounts of vector RNA in each
of the stocks as determined by quantitative RT-PCR—in general the
amounts of vector RNAs in the different stocks were similar.
Reverse transcription-real time quantitative PCR
Total RNA was isolated from vector stocks using the RNeasy Mini
Kit (Qiagen, Inc.) according to manufacturer's instructions. Isolated
RNA was treated with DNase I (Qiagen, Inc.) and reverse transcribed
(or not) with SuperScript III (Invitrogen, Inc.). For quantiﬁcation of
MLV retroviral vector RNA levels, cDNA was ampliﬁed with the
following primer pair detecting the EGFP gene: 5′-ACG TAA ACG GCC
ACA AGT TC-3′ and 5′-AAG TCG TGC TGC TTC ATG TG-3′. RT-qPCR was
performed using the ABI 7900 real-time PCR machine as previously
described (Okeoma et al., submitted for publication).
Western blots
To prepare vector stocks for western analysis, 100 µl of vector stock
was diluted in 30% sucrose in 1×PBS, and pelleted at 21,000 rpm in a
SW28 rotor for 1 h at 4 °C. The pellet was then resuspended in virion
lysis buffer containing 25 mM Tris–HCl (pH8), 150 mM NaCl, 2 mM
EDTA, 0.1% SDS, 0.5% Nonidet P-40, 0.5% deoxycholic acid. Equal
portions of the vector stocks were loaded, separated by 12% SDS-PAGE
and electrophoretically transferred to a nitrocellulose membrane. For
quantiﬁcation of viral protein in the vector stocks, the membrane was
incubated with a primary rabbit polyclonal antibody for M-MuLV p30
(CA) protein (1:3333 dilution; Mueller-Lantzsch and Fan, 1976),
followed by washing and incubation with a horseradish peroxidase-
conjugated secondary antibody (donkey anti-rabbit IgG, Amersham).The blots were also probed with anti-HA (Invitrogen, Inc., Carlsbad,
CA) and species-appropriate HRP-conjugated secondary antibody was
used to detect the mA3HA or mA3Δexon5HA proteins. Bands were
detected with ECL reagents (Amersham Biosciences, Inc.) and X-ray
ﬁlm.
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